FDA 483 - VitalScientific B.V. - November 05, 2018

During an inspection of ELITechGroup B.V. in Spankeren, Netherlands, the FDA observed two issues related to the firm's device manufacturing processes. The observations highlight inadequate procedures for accepting incoming products and deficiencies in establishing training and identifying training needs for employees. These findings indicate a need for improved quality system controls within the facility.